
Y, et al. on behalf of the OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. n Engl j Med 2011; 364:422–31. 3. Golan Y, Epstein L. Safety and efficacy of fidaxomicin in the treatment of Clostridium difficile–associated diarrhea. Therap adv Gastroenterol 2012; 5:395–402. 4. Astellas Pharma Europe. Dificlir (Fidaxomicin) [prescribing information]. Leiden, Netherlands: Astellas Pharma Europe; 2012. 5. Windpessl M, Wallner M. M.3243A>G: many faces of one single point mutation. Wien Klin Wochenschr 2010; 122:601. 6. Cope TE, McFarland R, Schaefer A. Rapid-onset, linezolidinduced lactic acidosis in MELAS. Mitochondrion 2011; 11:992–3. doi:10.3747/pdi.2013.00040
Aged, 80 and over, Male, Humans, Pseudomonas Infections, Peritonitis, Peritoneal Dialysis
Aged, 80 and over, Male, Humans, Pseudomonas Infections, Peritonitis, Peritoneal Dialysis
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 6 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
